Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
Go back to Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico| Com-Guard.com, Inc. (AMEX: GUD) | Delayed: 0.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.00 | 52 Week High | $0.00 | |||
| Open | $0.00 | 52 Week Low | $0.00 | |||
| Day High | $0.00 | P/E | N/A | |||
| Day Low | $0.00 | EPS | $0.00 | |||
| Volume | 4,000 | |||||
| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 113.63 -0.12 (0.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $113.75 | 52 Week High | $118.49 | |||
| Open | $115.48 | 52 Week Low | $55.00 | |||
| Day High | $115.48 | P/E | N/A | |||
| Day Low | $113.18 | EPS | $-0.56 | |||
| Volume | 421,348 | |||||
